RNTX
Rein Therapeutics Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$0.89
+5.39%Aug 14, 2026, 10:44 UTC
Rein Therapeutics reported its financial results for the second quarter ended June 30, 2026.
Source:Aug 4, 2026, 12:00 UTC
Rein Therapeutics announced publication of first-in-human clinical data for LTI-03 in Nature Communications, supporting its ongoing Phase 2 RENEW trial for idiopathic pulmonary fibrosis.
Source:Jul 21, 2026, 12:00 UTC
Rein Therapeutics announced that its Phase 2 RENEW clinical trial is now open and enrolling patients across all five planned countries.
Source: